
A new and highly targeted drug slowed the growth of advanced breast cancers by about an average of two months, researchers report. “The findings in this study show a modest benefit to a subgroup of women with estrogen receptor-positive tumors,” said Dr. Stephanie Bernik, a breast cancer specialist who wasn’t involved in the research. Estrogen… read on >